Different toxicity rating patients and physicians in randomized phase III PCI vs obs stage III NSCLC

Published in:
Radiotherapy and Oncology

DOI:
10.1016/S0167-8140(18)31675-X

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
investigated if the MTHFR C677T polymorphism modulates the risk of developing breast, rectal and lung cancer.

**Material and Methods**
Genotyping was performed by PCR-RFLP method on a sample of 103 patients diagnosed with histologically proven cancer (52 rectal, 26 lung, and 25 breast) and 186 healthy controls, respectively (60, 101, 25).

**Results**
Analyses of affected and controls show that homozygote genotype MTHFR 677CC has the highest frequency in both groups. In lung cancer localization, it was 63.38% in patients and 45.5% in control group. In breast localization the distribution of the CC, CT and TT genotypes corresponded respectively to the proportions 40%, 55% and 5%. The odds ratio for the TT and CT genotypes was 1.42 (95% CI = 0.42-4.85) and the odds ratio for the TT and CT genotypes was 1.26 (95% CI = 0.07-21.49) and 0.69 (95% CI 0.21-2.29. We also demonstrated a modest increase in the risk of breast cancer in individuals with TT genotype compared to the general population (OR = 1.26; 95% CI = 0.07-21.49).

**Conclusion**
Despite the low rate of enrolled population in our study, we can conclude based on the results of our study that a significant association between lung, rectal cancer and C677T polymorphism might exist.

**EP-1365**
F-FDG-PET/CT metabolic features as prognostic and predictive factors in lung tumors undergoing SBRT

**Purpose or Objective**
Stereotactic body radiation therapy (SBRT) is an effective treatment for patients with lung tumors (both primitive and secondary) who are not candidates for surgery. For patients treated with SBRT, there are relatively few studies that examined predictors of regional and/or distant progression and agreement among them is poor. As several studies have shown that the analysis of baseline F-FDG PET/CT features has predictive and prognostic significances in several types of cancers, including oropharyngeal, esophageal and sarcoma, we hypothesized that imaging-based features could identify patients with lung tumors treated with SBRT who are at highest risk for progression. The aim of this study is to assess the prognostic impact and predictive role of the maximum standardized uptake value (SUV max), the metabolic tumor volume (MTV), the total lesion glycolysis (TLG) and SUV max lesion/SUV max liver (rPET) and their correlation with local control, overall survival (OS) and progression-free survival (PFS) in patients treated with stereotactic body radiation therapy (SBRT) for primitive or secondary lung tumors undergoing pretreatment [F-18 fluoro- D-glucose-positron emission tomography/ computed tomography (F-FDG PET/CT) imaging.

**Material and Methods**
Between September 2009 to December 2016, 70 patients with 85 medically inoperable lung tumors were treated with SBRT and underwent a F-FDG PET/CT before the treatment. Median age was 73 years. SBRT schedules were 60/55/50 Gy in 5 fractions or 54 Gy in 3 fractions. The effects of clinical-pathological factors including primary tumor SUV max, MTV, TLG and rPET on OS, PFS and local control (LC) were evaluated. Kaplan-Meier survival curves were produced and compared with the log-rank test.

**Results**
With a median follow-up for the population of 26 months, the median OS and PFS were 39.7 and 30.1 months, respectively. The 12- and 24-months OS for the entire cohort were 94% and 76%, respectively, with a 12- and 24-months PFS of 81% and 60%, respectively. On univariate analysis SUV max of tumor, (cut-off: 10), showed a mild correlation with OS, even if statistical significance has not been achieved (p= 0.611) (figure).
Purpose or Objective
The NVALT-11/ DLCRG-02 randomized trial showed that PCI reduced the incidence of symptomatic brain metastases from 30.7% to 8.1%. Here, we report the differences between the adverse events (AE) reporting between patients and physicians.

Material and Methods
Randomization between PCI or observation in radically treated stage III NSCLC. Primary endpoint: incidence of symptomatic brain metastases; secondary endpoints: OS, AE reported by patients and physicians, QoL.

Results
175 patients were randomized, 87 PCI and 88 treated stage III NSCLC. Primary endpoint: incidence of symptomatic brain metastases; secondary endpoints: OS, AE reported by patients and physicians, QoL.

Patients reported AE: dizziness, headache, hypersomnia, memory impairment and vomiting. For patients, only observation.

Differences between patients and physicians.

Inflammation plays a central role in the development of both lung cancer and cardiovascular disease (CVD) and CVD is frequently seen in patients with non-small cell lung cancer (NSCLC). Chronic inflammation is associated with an increased cell turnover with the potential of generating genetic errors, stimulate angiogenesis, and apoptosis and plays a role in the pathogenesis of CVD with an influence on all stages of the disease. We hypothesized that self-reported CVD is an independent risk factor for survival in lung cancer. Our hypothesis was studied in a prospective multicenter cohort study.

Material and Methods
Prospective multicenter data from 345 consecutive NSCLC patients that were seen in consultation in the radiation oncology departments of 2 Institutions from January 2013 to January 2017 was available. Median follow-up was 13 months (range, 0.1–45 months). Thirty-two percent of patients (N=109) had baseline CVD. Specifically, 29 patients (27%) had arrhythmia, 10 (9%) hypertensive CVD, 9 (8%) heart failure, 5 (5%) valvulopathy, 40 (37%) ischaemic heart disease, and 16 (15%) others. A total of 289 patients (82%) were treated with platinum-based chemotherapy (CT), 41% of them concomitant with radiation therapy (RT); 300 patients (87%) received thoracic RT; and 50 (15%) patients underwent surgery. Clinical-pathological and therapeutic characteristics were assessed for overall survival (OS) as primary endpoint using univariate and multivariate COX regression analysis.

Results
Our cohort consisted of 305 men (88%) and 40 (12%) women, with a median age of 67 years old (range, 31–88 years). Most of them (70%) had a Karnofsky performance status (KPS) ≤80. The most common histologies were adenocarcinoma (36%) and squamous cell carcinoma (54%). Most of patients were stages IIIA (40%) and IIIB (40%). The median radiation dose was 61 Gy (range, 12–70). Multivariate analyses showed worse OS in patients with advanced stages (p=0.009). Patients treated with surgery, RT or CT associated with better OS (HR 0.36, p=0.001; HR 0.42, p=0.001; HR 0.46, p=0.001, respectively). CVD was associated with poorer OS (HR = 1.44; CI: 1.07–1.93; p=0.016). Additionally, CVD associated with a higher risk of distant metastasis (HR = 1.46; CI: 1.04–2.05; p=0.026). Within the CVD, we specifically found that hypertensive CVD and heart failure associated with lower OS (HR = 1.92; CI: 1.14–3.24; p=0.013)

Conclusion
Self-reported CVD is associated with worse OS and higher risk of distant metastasis in NSCLC patients. Chronic inflammation associated with CVD seems to be a major pathophysiologic factor in the development of distant metastasis. Our genetic constitution may be crucial for the susceptibility of a distinct inflammation, a task for future studies.

Purpose or Objective
Inflammation plays a central role in the development of both lung cancer and cardiovascular disease (CVD) and CVD is frequently seen in patients with non-small cell lung cancer (NSCLC). Chronic inflammation is associated with an increased cell turnover with the potential of generating genetic errors, stimulate angiogenesis, and apoptosis and plays a role in the pathogenesis of CVD with an influence on all stages of the disease. We hypothesized that self-reported CVD is an independent risk factor for survival in lung cancer. Our hypothesis was studied in a prospective multicenter cohort study.

Purpose or Objective
The EP-1368 Lung cancer 3D-CRT: Evaluation of V5 constraint compliance and incidence of radiation pneumonitis

Purpose or Objective
Inflammation plays a central role in the development of both lung cancer and cardiovascular disease (CVD) and CVD is frequently seen in patients with non-small cell lung cancer (NSCLC). Chronic inflammation is associated with an increased cell turnover with the potential of generating genetic errors, stimulate angiogenesis, and apoptosis and plays a role in the pathogenesis of CVD with an influence on all stages of the disease. We hypothesized that self-reported CVD is an independent risk factor for survival in lung cancer. Our hypothesis was studied in a prospective multicenter cohort study.

Material and Methods
Prospective multicenter data from 345 consecutive NSCLC patients that were seen in consultation in the radiation oncology departments of 2 Institutions from January 2013 to January 2017 was available. Median follow-up was 13 months (range, 0.1–45 months). Thirty-two percent of patients (N=109) had baseline CVD. Specifically, 29 patients (27%) had arrhythmia, 10 (9%) hypertensive CVD, 9 (8%) heart failure, 5 (5%) valvulopathy, 40 (37%) ischaemic heart disease, and 16 (15%) others. A total of 289 patients (82%) were treated with platinum-based chemotherapy (CT), 41% of them concomitant with radiation therapy (RT); 300 patients (87%) received thoracic RT; and 50 (15%) patients underwent surgery. Clinical-pathological and therapeutic characteristics were assessed for overall survival (OS) as primary endpoint using univariate and multivariate COX regression analysis.

Results
Our cohort consisted of 305 men (88%) and 40 (12%) women, with a median age of 67 years old (range, 31–88 years). Most of them (70%) had a Karnofsky performance status (KPS) ≤80. The most common histologies were adenocarcinoma (36%) and squamous cell carcinoma (54%). Most of patients were stages IIIA (40%) and IIIB (40%). The median radiation dose was 61 Gy (range, 12–70). Multivariate analyses showed worse OS in patients with advanced stages (p=0.009). Patients treated with surgery, RT or CT associated with better OS (HR 0.36, p=0.001; HR 0.42, p=0.001; HR 0.46, p=0.001, respectively). CVD was associated with poorer OS (HR = 1.44; CI: 1.07–1.93; p=0.016). Additionally, CVD associated with a higher risk of distant metastasis (HR = 1.46; CI: 1.04–2.05; p=0.026). Within the CVD, we specifically found that hypertensive CVD and heart failure associated with lower OS (HR = 1.92; CI: 1.14–3.24; p=0.013)

Conclusion
Self-reported CVD is associated with worse OS and higher risk of distant metastasis in NSCLC patients. Chronic inflammation associated with CVD seems to be a major pathophysiologic factor in the development of distant metastasis. Our genetic constitution may be crucial for the susceptibility of a distinct inflammation, a task for future studies.